| Certain Balance Sheet Items Property, plant and equipment consisted of the following (in millions): | | | | | | | | | | | | | June 30,
2026 | | December 31,
2025 | | Manufacturing equipment and machinery | $ | 95.7 | | | $ | 97.4 | | | Land and buildings | 71.8 | | | 72.2 | | | Construction-in-progress | 70.5 | | | 49.6 | | | Leasehold improvements | 65.6 | | | 63.6 | | | Computer software | 64.1 | | | 63.7 | | | Computer equipment | 24.2 | | | 21.9 | | | Furniture and fixtures | 10.6 | | | 10.0 | | | | | | | Subtotal | 402.5 | | | 378.4 | | | Less accumulated depreciation and amortization | (190.5) | | | (178.5) | | | Property, plant and equipment, net | $ | 212.0 | | | $ | 199.9 | |
Accrued liabilities consisted of the following (in millions): | | | | | | | | | | | | | June 30,
2026 | | December 31,
2025 | | Rebates and other sales deductions | $ | 528.0 | | | $ | 459.8 | | | Employee compensation and benefits | 120.3 | | | 215.4 | | | | | | | Inventory-related accruals | 63.2 | | | 34.0 | | | Accrued royalties | 44.6 | | | 47.1 | | | Accrued interest | 39.8 | | | 40.7 | | | Consulting and professional services | 32.1 | | | 23.0 | | | Sales return reserve | 28.7 | | | 26.4 | | | Clinical trial accruals | 28.1 | | | 42.0 | | | Selling and marketing accruals | 24.9 | | | 15.4 | | | Accrued development expenses | 16.4 | | | 24.4 | | | | | | | Current portion of lease liabilities | 14.3 | | | 14.7 | | | Accrued construction-in-progress | 9.9 | | | 14.3 | | | Derivative instrument liabilities | 8.6 | | | 4.2 | | | | | | | | | | | | | | | Other | 71.1 | | | 72.8 | | | Total accrued liabilities | $ | 1,030.0 | | | $ | 1,034.2 | |
|